Most Popular - Weight-loss drug makers popped Wednesday morning after mega-insurer Aetna (NYSE:AET) issued a bulletin on weight reduction medications and procedures. Qysmia, from Vivus (NASDAQ:VVUS), and Arena’s … Continue Reading
Read nowMost Popular - Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares … Continue Reading
Read nowMost Popular - Our earnings preview supposed that in-line QCOR earnings could improve share price. QCOR delivered well-above estimates, but shares remained flat following, as reimbursement concerns still linger. … Continue Reading
Read nowQuick Picks - Word from Orexigen Therapeutics (NASDAQ:OREX) Wednesday that it will be raising capital in the form of an equity offering came as little surprise to investors, … Continue Reading
Read nowQuick Picks - The competition among obesity-drug makers continues to heat up Monday following an announcement from Orexigen Therapeutics (NASDAQ:OREX) that the company may be able to expedite the approval … Continue Reading
Read nowLong Ideas - Orexigen Therapeutics (NASDAQ:OREX) continues this week’s gains in early trading on Thursday, up roughly 20% to $5.35 since Tuesday. The strength comes from Orexigen’s announcement … Continue Reading
Read now- Vivus (NASDAQ:VVUS) announced FDA approval of its anti-obesity drug, Qsymia, last night and importantly, physicians can prescribe the medicine to patients without major restrictions. The … Continue Reading
Read now